Blinatumomab

BLINCYTO®

Overview

Blinatumomab is an anti-CD19/anti-CD3 bi-specific T cell engager that is approved to treat acute lymphoblastic leukemia and being studied for use in other indications. 

SparkCures ID 362
Brand Name Blincyto®
Generic Name Blinatumomab
Treatment Classifications
Treatment Targets

Clinical Trials

Resources

There are no resources, links or videos to display for this treatment.